Skip to main content

Table 3 Characteristics of LOX-low/LOX-high extramedullary AML

From: Lysyl oxidase expression is associated with inferior outcome and Extramedullary disease of acute myeloid leukemia

  all EM AML
n = 59
all EM AML
n = 59
LOX-low group
n = 28, 60%
LOX-high group
n = 31, 40%
p-value
age at diagnosis
median (range)
46 (17–60) 45 (17–60) 49 (22–59) 0.538
Gender, Female, no. (percent) 24 (41) 13 (46) 11 (35) 0.393
Bone marrow blasts at diagnosis
[percent] median (range)
63 (20–96) 68.5 (20–94) 62.5 (20.5–96) 0.792
WBC count at diagnosis
[Gpt/L] median (range)
26.9 (1.3–191.4) 38 (1.4–191.4) 18.8 (1.3–189.1) 0.370
Platelet count at diagnosis
[Gpt/L] median (range)
52 (13–357) 61 (13–231) 50 (13–357) 0.970
Serum LDH at diagnosis
[U/l] median (range)
707 (145–4945) 694 (186–4945) 768 (145–3973) 0.439
FLT3-ITD mutational status, positive, no. (percent) 12 (25) 8 (29) 4 (13) 0.135
NPM1 mutational status, NPM1 mut, no. (percent) 21 (36) 10 (37) 11 (35) 0.902
Combined NPM1/FLT3 status, no. (percent)
NPM1 wt/FLT3 wt 32 (55) 14 (52) 18 (58) 0.413
NPM1 wt/FLT3 mut 5 (9) 3 (11) 2 (6)
NPM1 mut/FLT3 wt 14 (24) 5 (18) 9 (29)
NPM1 mut/FLT3 mut 7 (12) 5 (18) 2 (6)
Disease status at diagnosis, no. (percent)
 De novo AML 53 (90) 28 (100) 25 (81) 0.049
 tAML 5 (8) 0 (0) 5 (16)
 mdsAML 1 (2) 0 (0) 1 (3)
FAB subtypes at diagnosis, no. (percent)
 M0 2 (3) 0 (0) 2 (6) 0.003
 M1 11 (19) 9 (32) 2 (6)
 M2 14 (24) 10 (36) 4 (13)
 M4 9 (15) 2 (7) 7 (23)
 M4eo 2 (3) 2 (7) 0 (0)
 M5a 11 (19) 1 (4) 10 (32)
 M5b 2 (3) 0 (0) 2 (6)
 M6 2 (3) 1 (4) 1 (3)
 M7 1 (2) 0 (0) 1 (3)
 RAEB-T 3 (5) 1 (4) 2 (6)
 M5 other 2 (3) 2 (7) 0 (0)
Cytogenetic subgroups, no. (percent)
 High risk 19 (32) 3 (11) 16 (52) 0.001
 Standard risk 33 (56) 19 (68) 14 (45)
 Low risk 7 (12) 6 (21) 1 (3)
Detailed karyotypes, no. (percent)
 Complex karyotype 12 (20) 3 (11) 9 (29) 0.081
 Normal karyotype 18 (32) 12 (44) 6 (20) 0.047
 t(8;21) 4 (7) 3 (11) 1 (3) 0.253
 inv16 3 (5) 3 (11) 0 (0) 0.061
 monosomy 5 2 (3) 0 (0) 2 (6) 0.171
 del5q 3 (5) 1 (4) 2 (6) 0.615
 monosomy 7 1 (2) 1 (4) 0 (0) 0.289
 del7q 3 (5) 1 (4) 2 (6) 0.615
 monosomy other than chromosomes 5 or 7 3 (5) 1 (4) 2 (6) 0.615
 trisomy 8 11 (19) 3 (11) 8 (26) 0.137
 t(9;11) 3 (5) 0 (0) 3 (10) 0.091
 abnl(11q23) 10 (17) 1 (4) 9 (29) 0.009
  1. Table 3 Univariate results of EM-AML patients’ characteristics, divided in LOX-low and LOX-high group
  2. Abbreviations: AML acute myeloid leukemia, FAB French American British classification of acute leukemia, FLT3-ITD FMS-like tyrosine kinase 3 internal tandem duplication, LDH lactate dehydrogenase, MDS myelodysplastic syndrome, NPM1 Nucleophosmin 1, RAEB refractory anemia with excess blasts, t-AML therapy-related AML, mdsAML AML with preceding MDS, WBC white blood count